Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Rising Prostate Specific Antigen (PSA): early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Rising Prostate Specific Antigen (PSA): 1 US clinical trial tracked, none currently recruiting.

Rising Prostate Specific Antigen (PSA) is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Tyme, running 1 of these trials.

Enrollment posture brief

Registry condition rising-prostate-specific-antigen-psa

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Rising Prostate Specific (th…0%
Open-enrollment share among volume-matched conditions near Rising Prostate Specific Antigen (PSA)

Rising Prostate Specific Antigen (PSA) has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Rising Prostate Specific Antigen (PSA) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Rising Prostate Specific Antigen (PSA) is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Tyme 1 trials

Named interventions

Most-linked intervention names on Rising Prostate Specific Antigen (PSA) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

SM88 (Cohort 2) Drug
1 trials
SM88 (Cohort 1) Drug
1 trials

US sites by state

Facility locations filed on Rising Prostate Specific Antigen (PSA) trials. A trial with sites in several states counts in each.

Pennsylvania 1 trials
New York 1 trials
New Jersey 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Rising Prostate Specific Antigen (PSA) page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Rising Prostate Specific Antigen (PSA) trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Tyme sponsors the most Rising Prostate Specific Antigen (PSA) trials on record, review their full trial history before evaluating a specific study. See Tyme's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Rising Prostate Specific Antigen (PSA) condition card totals 1 registered trials; most-linked intervention SM88 (Cohort 2); top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.